Introduction
Pazorest 200 mg (Pazopanib Hydrochloride) is an advanced oral oncology treatment developed by Everest Pharmaceuticals Ltd. It is a powerful multi-kinase inhibitor used primarily in the treatment of advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have undergone prior chemotherapy. Onco Solution, a global supplier of oncology medicines, ensures the reliable availability of Pazorest for healthcare providers and patients around the world.
Key Benefits
- Effective for advanced renal cell carcinoma (RCC)
- Treats soft tissue sarcoma (STS) post-chemotherapy
- Oral once-daily dosage for patient convenience
- Globally accessible through Onco Solution
Indications
Pazorest is indicated for:
- Patients with advanced renal cell carcinoma (RCC)
- Patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy
Note: Pazorest is not recommended for the treatment of adipocytic STS or gastrointestinal stromal tumors.
Dosage & Administration
- Recommended dose: 800 mg orally once daily on an empty stomach (at least 1 hour before or 2 hours after meals)
- Tablets should not be crushed or chewed
- If a dose is missed and it’s less than 12 hours before the next dose, skip the missed dose
Always follow the guidance of a registered healthcare professional.
Pharmacology
Pazopanib is a selective multi-tyrosine kinase inhibitor targeting:
- VEGFR-1, 2, 3
- PDGFR-α and -β
- FGFR-1 and -3
- c-Kit, Itk, Lck, and c-Fms
Absorption: Peak concentrations within 2 to 4 hours after oral administration.
Distribution: >99% plasma protein bound.
Metabolism: Primarily by CYP3A4; minor contributions from CYP1A2 and CYP2C8.
Elimination: Mean half-life is approximately 30.9 hours; excreted mostly in feces.
Drug Interactions
- Avoid strong CYP3A4 inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir)
- Avoid CYP3A4 inducers (e.g., Rifampin)
- Avoid P-gp and BCRP inhibitors (e.g., Verapamil)
- Caution with Simvastatin due to increased liver enzyme levels
Grapefruit juice should be avoided as it may increase Pazorest concentration.
Contraindications
- Hypersensitivity to Pazopanib or any of its components
Common Side Effects
- Hepatotoxicity
- Hypertension
- QT prolongation
- Hemorrhagic events
- Gastrointestinal perforation
- Interstitial lung disease
- Proteinuria
- Hypothyroidism
- Tumor lysis syndrome
Warnings & Precautions
- Monitor liver function regularly, especially in patients over 65
- Perform ECG monitoring for QT prolongation
- Advise patients on potential cardiac, hepatic, and renal complications
- Risk of fetal harm; recommend contraception for both males and females during and 2 weeks after treatment
- Avoid breastfeeding during and 2 weeks post-treatment
Use in Special Populations
- Pediatric: Not established
- Geriatric: Caution due to increased risk of hepatic toxicity
- Pregnancy & Lactation: Contraindicated
Overdose Information
- Doses up to 2000 mg evaluated in clinical trials
- Dose-limiting toxicities include fatigue and hypertension
- No specific antidote; manage with supportive care
Storage
- Store below 30°C
- Keep in a dry, cool place
- Protect from sunlight and keep out of reach of children
About the Manufacturer
Everest Pharmaceuticals Ltd is a trusted name in pharmaceutical innovation, offering world-class manufacturing standards and therapies across multiple therapeutic areas, especially oncology. Visit everestpharmabd.com to learn more.
Supplier Profile: Onco Solution
Onco Solution is a worldwide supplier of oncology medicines, dedicated to improving global access to quality cancer therapies. Partnering with leading manufacturers like Everest Pharmaceuticals Ltd, Onco Solution bridges the gap between innovation and accessibility. Learn more at oncosolution.com.
